Biomega Group has appointed its interim chief financial officer, Espen Aarstad, to the position in a permanent capacity.
The Bergen, Norway-based ingredient supplier to the health and nutrition industry provides sustainable salmon ingredients for the human and pet health sectors.
Aarstad, who was named the company’s interim CFO since last fall, will officially be promoted on 1 March, 2021. Previously, he worked in finance positions at several Norwegian manufacturing companies, including serving as group CFO at Totaltek AS and at Protan AS.
“It is a pleasure to join the Biomega team, particularly as the company accelerates its 2021 strategic plans,” Aarstad said. “Biomega has seen rapid growth in the past couple of years and I’m truly excited to be involved in such an ambitious investment strategy. This year will see the Biomega brand achieve new heights in performance as we investigate the numerous health opportunities for human-grade salmon ingredients.”
Aarstad’s promotion fills out the Norwegian-based company’s leadership team, following the appointment of Stig Victor Petersen as CEO in October 2020. In a press release, Petersen said the company’s strategy remains focused on “advancing biotechnology to release the full nutritional and functional value of underutilized side streams in the salmon industry.”
“Since Espen stepped in as interim CFO last year, he has provided the leadership team with accelerated business insight based on a wealth of knowledge obtained through previous positions. His strong financial capabilities, combined with a passion for biotechnology and manufacturing, will provide us with great direction as we move further into 2021,” Petersen said.
Biomega has been able to develop proprietary biotechnology that allows it to transform high-quality raw material into premium food and feed ingredients, including hydrolyzed salmon proteins (salmon peptides) and salmon oil, which it manufactures at its biorefinery in Norway
“Aarstad will take a pivotal position in the company as Biomega continues to invest in its proprietary R&D technology as part of an ambitious expansion strategy, exploring upcoming opportunities in the human nutrition market,” the company said in its release.
Photo courtesy of Biomega